Protocol Ledger

NCT03859700 · Phase III · COMPLETED

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

Interventional Phase III clinical trial protocol NCT03859700 sponsored by DBV Technologies in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-06 Enrollment: 304 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03859700
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)304 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03859700
Protocol FieldVerified Registry Value
NCT IdentifierNCT03859700
Consolidated Lead SponsorDBV Technologies
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment304 participants (ACTUAL)
Registered Start Date2018-12-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI